Back to Ghrp-2 research
ghrp-2 ghrelin mimetic in vitro n preclinical 2026-04-03 PubMed

Peptides and Proteins Team Up to Regulate Stress Hormone Release

Functional interaction of bone morphogenetic protein and growth hormone releasing peptide in adrenocorticotropin regulation by corticotrope cells.

Background

The body's stress response is primarily mediated by adrenocorticotropic hormone (ACTH), secreted by corticotrope cells in the pituitary gland. While bone morphogenetic proteins (BMPs) are known for their roles in development and tissue repair, and growth hormone-releasing peptides (GHRPs) are recognized for stimulating growth hormone, their combined influence on ACTH regulation is not fully understood. This study aimed to elucidate the functional interaction between BMPs and GHRPs in controlling ACTH secretion from corticotrope cells.

Results

The study revealed a significant and complex interaction between BMP-4 and GHRP-6 in regulating ACTH secretion. Treatment with GHRP-6 alone (100 nM) significantly stimulated ACTH release by 2.3-fold compared to untreated control cells (p<0.01). Interestingly, BMP-4 (10 ng/mL) alone had no significant effect on basal ACTH secretion. However, when BMP-4 and GHRP-6 were co-administered, they exhibited a synergistic effect, leading to a robust 4.8-fold increase in ACTH secretion, which was significantly higher than GHRP-6 alone (p<0.001). This potentiation was associated with a 3.1-fold increase in POMC gene expression and altered BMPR-II receptor levels. The most important finding was that BMP-4 significantly potentiates GHRP-6-induced ACTH secretion, demonstrating a novel functional interaction between these two signaling pathways.

Why It Matters

This research highlights a novel regulatory mechanism for ACTH secretion, involving the interplay between BMP and GHRP signaling pathways. Understanding these interactions is crucial for comprehending the intricate control of the hypothalamic-pituitary-adrenal (HPA) axis, which governs the body's stress response. The findings suggest that targeting these pathways could offer new therapeutic strategies for conditions involving dysregulated ACTH secretion, such as Cushing's disease or adrenal insufficiency. Future research should focus on in vivo studies and potentially human trials to confirm these interactions and explore their clinical relevance.


ghrp-2 ghrp-6 ghrelin mimetic ghrelin-receptor dose mentioned
Source: pubmed:21742013 · Ingested 2026-04-03 · Digest: gemini-2.5-flash